definiens: ) to the ORIGINAL LICENSE as defined below, is madc by and between the BOARD OF REGENTS ( ) of THE UNIVERSITY OF TEXAS SYSTEM ( ), an agency of the State of Texas, whose address is 201 West 7th Strect, Austin, Texas 78701, on behalf of THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER ( hereafter ), a component institution of SYSTEM, and ARONEX PHARMACEUTICALS, INC ., a Delaware corporation having a principal place of business located at 3 Forbes Road, Lexington, Massachusetts 02421 ( ), a wholly owned subsidiary of ANTIGENICS INC ., a Delaware corporation . BOARD and LICENSEE may be refelTed to hereafter collectively as the RECITALS A. BOARD and ARGUS PHARMACEUTICALS, INC ., executed an Exclusive License Agreement dated effective as of July 22, 1988 ( such Exclusive License Agreement, as amended, refened to herein as the ) ; B. LICENSEE is the successor in interest to ARGUS PHARMACEUTICALS, INC . ; C. The PARTIES have reached an agreement to return rights to certain technologies to BOARD ( as defined below ) ; D. The PARTIES have further agreed that LICENSEE will provide celiain information relating to the RETURNED TECHNOLOGY to UTMDACC ; NOW, THEREFORE, in consideration of the mutual covenants contained herein, the sufficiency of which is hereby acknowledged, the patiies hereby agree to the following : AMENDED TERMS 1 . Schedule Ito the ORIGINAL LICENSE is hereby amended to exclude the RETURNED TECl - INOLOGY ( as defined below ) . The amended Schedule I is attached hereto